Edition:
United Kingdom

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

30.23USD
15 Dec 2017
Change (% chg)

$-0.05 (-0.17%)
Prev Close
$30.28
Open
$30.29
Day's High
$30.58
Day's Low
$29.54
Volume
1,025,996
Avg. Vol
179,455
52-wk High
$32.17
52-wk Low
$11.30

Chart for

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $1,019.33
Shares Outstanding(Mil.): 39.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China

* ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA

05 Dec 2017

BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.86

* Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results

07 Nov 2017

BRIEF-Arena Pharmaceuticals Q2 loss per share $0.77

* Arena Pharmaceuticals provides corporate update and reports second quarter 2017 financial results

07 Aug 2017

BRIEF-Arena Pharmaceuticals says public offering of 6.25 mln common shares priced at $24 per share

* Arena Pharmaceuticals announces pricing of public offering of common stock

13 Jul 2017

BRIEF-Arena Pharmaceuticals announces proposed public offering of common stock

* Arena Pharmaceuticals announces proposed public offering of common stock

11 Jul 2017

Arena's heart-lung drug succeeds in mid-stage study, shares soar

U.S. drug developer Arena Pharmaceuticals Inc said on Monday its experimental drug for pulmonary arterial hypertension (PAH), a rare but deadly lung disease, met the main goal in a mid-stage study.

10 Jul 2017

Competitors

Earnings vs. Estimates